

**Figure S1**

| Case                            | 1          | 2         | 3          | 4                                    | 5       | 6                      | 7         | 8          | 9       | 10         | 11                               | 12       | 13      | 14        | 15      | 16                        | 17        | 18      | 19      |
|---------------------------------|------------|-----------|------------|--------------------------------------|---------|------------------------|-----------|------------|---------|------------|----------------------------------|----------|---------|-----------|---------|---------------------------|-----------|---------|---------|
| Age at LDLT (month)             | 2          | 9         | 6          | 8                                    | 9       | 9                      | 7         | 11         | 5       | 7          | 4                                | 6        | 6       | 6         | 4       | 10                        | 1         | 6       | 5       |
| Gender                          | Female     | Male      | Male       | Female                               | Male    | Female                 | Female    | Female     | Female  | Female     | Female                           | Male     | Female  | Female    | Male    | Female                    | Female    | Female  | Female  |
| Primary disease                 | ALF        | BA        | BA         | mitochondrial DNA depletion syndrome | ALF     | Methylmalonic acidemia | BA        | BA         | BA      | BA         | glycogen storage disease type IV | BA       | BA      | BA        | BA      | Maple syrup urine disease | ALF       | BA      | BA      |
| PELD                            | 36         | 19        | 25         | 14                                   | 25      | 2                      | 12        | 19         | 15      | 21         | 2                                | 9        | 13      | 37        | 14      | -4                        | 50        | 12      | 9       |
| Blood type combination          | A→O        | B→O       | A→O        | AB→A                                 | A→B     | A→O                    | A→B       | A→B        | B→A     | A→B        | A→O                              | B→O      | B→O     | AB→A      | AB→A    | A→O                       | AB→A      | A→O     | B→O     |
| Lymphocyte crossmatch           | No data    | -         | -          | T-B+                                 | -       | -                      | No data   | No data    | No data | No data    | -                                | No data  | -       | -         | -       | -                         | -         | -       | T-B+    |
| PE                              | +          | +         | +          | -                                    | -       | +                      | +         | +          | -       | -          | -                                | -        | -       | -         | -       | -                         | -         | -       | -       |
| Anti-donor IgM/IgG at admission | 1:64/1:256 | 1:64/1:64 | 1:64/1:64  | 1:2/1:1                              | 1:4/1:1 | 1:64/1:64              | 1:64/1:32 | 1:128/1:64 | 1:8/1:4 | 1:128/1:32 | 1:8/1:4                          | 1:16/1:8 | 1:8/1:4 | 1:32/1:16 | 1:1/1:1 | 1:16/1:8                  | 1:32/1:32 | 1:2/1:1 | 1:2/1:1 |
| Anti-donor IgM/IgG at LDLT      | 1:1/1:8    | 1:1/1:1   | 1:4/1:16   | 1:2/1:1                              | 1:4/1:1 | 1:8/1:4                | 1:2/1:1   | 1:4/1:1    | 1:8/1:4 | 1:128/1:32 | 1:8/1:4                          | 1:16/1:8 | 1:8/1:4 | 1:32/1:16 | 1:1/1:1 | 1:16/1:8                  | 1:32/1:32 | 1:2/1:1 | 1:2/1:1 |
| Anti-donor IgM/IgG after LDLT   | 1:2/1:8    | 1:64/1:32 | 1:128/1:64 | 1:2/1:2                              | 1:8/1:2 | 1:32/1:8               | 1:4/1:1   | 1:256/1:32 | 1:2/1:1 | 1:64/1:8   | 1:1/1:1                          | 1:2/1:1  | 1:2/1:1 | 1:1/1:1   | 1:1/1:1 | 1:16/1:4                  | No data   | 1:8/1:2 | 1:2/1:1 |
| CD19+ lymphocyte at LDLT (%)    | No data    | No data   | No data    | 28.1                                 | No data | No data                | No data   | No data    | No data | No data    | No data                          | No data  | No data | 30.7      | 25.8    | No data                   | No data   | No data | No data |
| AMR                             | -          | -         | -          | -                                    | -       | -                      | -         | -          | -       | -          | -                                | -        | -       | -         | -       | -                         | -         | -       | -       |
| Death (months)                  | -          | -         | -          | + (6)                                | -       | -                      | -         | -          | -       | -          | + (1)                            | -        | -       | -         | -       | -                         | + (10)    | -       | -       |

LDLT, living donor liver transplantation; BA, biliary atresia; ALF, acute liver failure; PELD, pediatric end-stage liver disease; PE, plasma exchange; AMR, antibody-mediated rejection